GSK Singapore: Overview of GlaxoSmithKline’s Singapore Operations
Welcome to the world of GSK Singapore! As a healthcare company with a global presence, GSK has been operating in Singapore since 1959. With over 1,500 employees in various roles and sectors, GSK produces vaccines and medicines that help improve the health and well-being of people around the world.
GSK’s operations in Singapore are diverse and include a state-of-the-art vaccine facility in Tuas, which is the largest vaccine production site in Singapore. The facility has been expanded with an investment of over $850 million, including the transfer of GSK’s next-generation process for hepatitis B vaccines. This investment has boosted Singapore’s biopharmaceutical innovation and helped establish the country as a global hub for sustainability leadership and innovation.
At GSK Singapore, talent and sustainability are at the forefront of our operations. We are committed to investing in our employees and providing them with opportunities to grow and develop their skills. We also recognise the importance of sustainability and are dedicated to reducing our environmental impact while continuing to provide high-quality products and services to our customers.
GSK’s Operations in Singapore
When it comes to biopharmaceutical manufacturing in Singapore, GSK is a leading contributor with a strong commitment to innovation, sustainability, and patient health. Here’s a closer look at GSK’s operations in Singapore.
Manufacturing Excellence at Tuas and Quality Road
GSK’s manufacturing sites in Singapore are located in Tuas and Quality Road. The Tuas facility is the largest vaccine production site in Singapore and one of the largest in Asia. The facility produces vaccines that protect against diseases such as Haemophilus Influenzae Type B, Hepatitis B, and COVID-19. The Quality Road site produces medicines and vaccines for the global supply chain, including oncology treatments.
Both sites are equipped with state-of-the-art technology and processes, including single-use bags, digital manufacturing, and quality control systems. GSK’s commitment to process improvement and innovation has led to a reduction in waste and energy consumption, making its manufacturing operations in Singapore more sustainable.
Innovation and Technology Advancements
GSK’s operations in Singapore are driven by innovation and technology advancements. The company has invested more than S$2.5 billion (£1.5 billion) in Singapore’s biopharmaceutical industry, including the construction of a new S$343 million state-of-the-art vaccines facility at Tuas, which will manufacture drug substances for GSK’s vaccines that protect against Hepatitis B. The facility is expected to be completed by 2025.
GSK is also committed to digital manufacturing and has implemented a range of technologies to improve efficiency, quality, and safety. For example, the company uses advanced analytics to monitor and optimize production processes, reducing the risk of errors and improving product quality.
Economic Impact and Partnerships
GSK’s operations in Singapore have a significant economic impact. The company employs more than 1,600 people in Singapore and contributes to the growth of the biopharmaceutical industry. GSK has also partnered with the Economic Development Board of Singapore to support the development of the biopharmaceutical industry in Singapore.
In addition, GSK has formed partnerships with other companies and organizations to advance research and development in areas such as vaccines, oncology, and sustainability. For example, GSK has partnered with Regis Simard to develop a green manufacturing plant in Jurong that uses renewable energy and sustainable materials.
Overall, GSK’s operations in Singapore are a testament to the company’s commitment to innovation, sustainability, and patient health. With its state-of-the-art manufacturing sites, cutting-edge technology, and strong partnerships, GSK is well-positioned to continue making a positive impact in the biopharmaceutical industry in Singapore and beyond.
Talent and Sustainability
GSK Singapore is committed to developing local talent and creating jobs in the biopharma industry. The company’s focus on talent development is evident in its investment in employee training and development programs. These programs are designed to help employees acquire new skills and knowledge to support their career growth within the company.
Developing Local Talent and Creating Jobs
GSK Singapore’s commitment to developing local talent is reflected in its efforts to create job opportunities for Singaporeans. The company’s investment in its manufacturing footprint in Singapore has resulted in the creation of new jobs in the biopharma industry. GSK Singapore’s Thermo Fisher and Sanofi mRNA facilities, as well as its Sinovac Biotech research facility, have created new job opportunities for Singaporeans in the areas of advanced manufacturing, high-potency manufacturing, and research.
Commitment to Green Manufacturing
GSK Singapore is committed to sustainability and green manufacturing. The company’s manufacturing facilities in Singapore are designed to reduce their environmental impact and promote sustainability. GSK Singapore’s commitment to sustainability is reflected in its investment in its manufacturing facilities, which are equipped with the latest technology to reduce energy consumption and waste.
GSK Singapore’s commitment to sustainability is also evident in its focus on the development of new vaccines and treatments for diseases such as Hib, invasive diseases, pneumonia, and meningitis. The company’s research and development efforts are focused on developing new treatments that are safe, effective, and environmentally friendly.
GSK Singapore’s commitment to sustainability and talent development has helped the company remain competitive in the biopharma industry. The company’s focus on talent development has resulted in a highly skilled workforce that is capable of developing and manufacturing innovative new treatments for cancer and other diseases.
In conclusion, GSK Singapore’s commitment to sustainability, talent development, and job creation has helped the company become a leader in the biopharma industry. The company’s investment in its manufacturing footprint in Singapore has resulted in the creation of new job opportunities for Singaporeans, while its commitment to sustainability has helped reduce its environmental impact. GSK Singapore’s focus on talent development has resulted in a highly skilled workforce that is capable of developing and manufacturing innovative new treatments for cancer and other diseases.
Frequently Asked Questions
What job opportunities are available at GSK in Singapore?
GSK Singapore offers a range of job opportunities across various functions, including research and development, manufacturing, sales and marketing, finance, human resources, and more. To view current job openings and apply, please visit the GSK career website.
Where can I find the address for GSK’s office in Singapore?
GSK’s office in Singapore is located at 23 Rochester Park, Singapore 139234. You can find directions and contact information on the GSK Singapore website.
Which products are offered by GSK in the Singapore market?
GSK offers a range of pharmaceutical and healthcare products in the Singapore market, including vaccines, prescription medicines, over-the-counter medicines, and consumer healthcare products. To learn more about our products, please visit the GSK Singapore website.
How can I get in touch with GSK in Singapore?
You can get in touch with GSK in Singapore by calling our customer service hotline at +65 6232 8338 or by filling out the contact form on the GSK Singapore website.
Who is the current CEO of GSK’s Singapore branch?
As of June 2024, the current CEO of GSK’s Singapore branch is not publicly disclosed.
How many employees are part of the GSK team in Singapore?
As of June 2024, GSK employs approximately 1,500 people in Singapore across various functions and locations.